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Abstract: Metformin has been linked to improve survival of patients with various cancers. There is little
information on survival of glioblastoma patients after use of metformin. We assessed the association
between metformin use and survival in a pooled analysis of patient data from 1,731 individuals from
the randomized AVAglio, CENTRIC and CORE trials. We performed multivariate Cox analyses for
overall survival (OS) and progression-free survival (PFS) comparing patients’ use of metformin at baseline
and/or during concomitant radiochemotherapy (TMZ/RT). Further exploratory analyses investigated the
effect of metformin with a history of diabetes and nonfasting glucose levels in relation to OS or PFS of
glioblastoma patients. Metformin alone or in any combination was not significantly associated with OS
or PFS (at baseline, hazard ratio [HR] for OS = 0.87; 95% confidence interval [CI] = 0.65-1.16; HR for
PFS = 0.84; 95% CI = 0.64-1.10; during TMZ/RT HR for OS = 0.97; 95% CI = 0.68-1.38; HR for PFS =
1.02; 95% CI = 0.74-1.41). We found a statistically nonsignificant association of metformin monotherapy
with glioblastoma survival at baseline (HR for OS = 0.68; 95% CI = 0.42-1.10; HR for PFS = 0.57;
95% CI = 0.36-0.91), but not during the TMZ/RT period (HR for OS = 0.90; 95% CI = 0.51-1.56; HR
for PFS = 1.05; 95% CI = 0.64-1.73). Diabetes mellitus or increased nonfasting glucose levels were not
associated with a difference in OS or PFS in our selected study population. Metformin did not prolong
survival of patients with newly diagnosed glioblastoma in our analysis. Additional studies may identify
patients with specific tumor characteristics that are associated with potential benefit from treatment with
metformin, possibly due to metabolic vulnerabilities.
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1 Abbreviations
2 CI = Confidence interval
3 HR = Hazard ratio
4 IDH = Isocitratedehydrogenase
5 MGMT = O6-Methylguanine DNA methyltransferase
6 MMSE = Mini-Mental State Exam
7 PFS = Progression-free survival
8 OS = Overall survival 
9 RT = Radiotherapy
10 TMZ = Temozolomide
11 WHO = World Health Organisation
12
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1 Abstract
2 Metformin has been linked to improved survival of patients with various cancers. 
3 There is little information on survival of glioblastoma patients after use of metformin. 
4 We assessed the association between metformin use and survival in a pooled analysis 
5 of patient data from 1,731 individuals from the randomized AVAGlio, CENTRIC and 
6 CORE trials. We performed multivariate COX-analyses for overall survival (OS) and 
7 progression-free survival (PFS) comparing patients’ use of metformin at baseline 
8 and/or during concomitant radio-chemotherapy (TMZ/RT). Further exploratory 
9 analyses investigated the effect of metformin with a history of diabetes and non-
10 fasting glucose levels in relation to OS or PFS of glioblastoma patients. 
11 Metformin alone or in any combination was not significantly associated with OS or 
12 PFS (at baseline, HR for OS=0.87; 95%CI=0.65-1.16; HR for PFS=0.84; 95%CI=0.64-
13 1.10; during TMZ/RT HR for OS=0.97; 95%CI=0.68-1.38; HR for PFS=1.02; 
14 95%CI=0.74-1.41). We found a statistically non-significant association of metformin 
15 monotherapy with glioblastoma survival at baseline (HR for OS =0.68; 95%CI=0.42-
16 1.10; HR for PFS=0.57; 95%CI=0.36-0.91), but not during the TMZ/RT period (HR for 
17 OS=0.90; 95%CI=0.51-1.56; HR for PFS=1.05; 95%CI=0.64-1.73). Diabetes mellitus or 
18 increased non-fasting glucose levels were not associated with a difference in OS or 
19 PFS in our selected study population.
20 Metformin did not prolong survival of patients with newly diagnosed glioblastoma in 
21 our analysis. Additional studies may identify patients with specific tumour 
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1 characteristics that are associated with potential benefit from treatment with 
2 metformin, possibly due to metabolic vulnerabilities.
3
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1 Novelty and Impact
2 The effect of Metformin in primary glioblastoma has not been proven so far in 
3 adequately designed trials. We prospectively evaluated the association between 
4 metformin use and survival in a pooled analysis of patient data from 1,731 individuals 
5 from three randomized trials. Metformin did not prolong survival of patients with 
6 newly diagnosed glioblastoma. Taken together, we conclude that metformin is not 
7 indicated in the treatment of patients with primary glioblastoma in their first 
8 diagnosis. 
9
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1 Introduction
2 Metformin is the most commonly prescribed agent in the treatment of type 2 
3 diabetes. Preclinical data and retrospective series suggest improved outcome in 
4 cancer patients1 receiving metformin inducing the initiation of clinical trials adding 
5 metformin to the standard anticancer treatment regimen. The mechanism of action 
6 remains elusive, a direct inhibitory effect on tumor cells2 as well as an indirect 
7 inhibition of cancer cells by lowering levels of circulating glucose and insulin and 
8 consequently lesser insulin-like growth-factor signalling have been postulated.3, 4 
9 Direct effects on tumor cells are related to inhibition of complex I of the respiratory 
10 chain with a downstream activation of the AMP-activated kinase and inhibition of the 
11 mammalian target of rapamycin.5 
12 Numerous studies investigated a potential inhibitory effect of metformin on cancer 
13 growth. In glioma models, several studies reported inhibitory effects on proliferation6-
14
10 and invasion11 in vitro and in vivo, and induction of cell death via apoptosis6, 9, 10 or 
15 autophagy.12 Possible inhibitory mechanisms of metformin have also prompted 
16 epidemiological studies as well as prospective clinical trials (reviewed in 1, 13, 14). 
17 Although extensively studied in other cancers, only three previous retrospective 
18 studies analysed survival of patients with glioblastoma with or without treatment with 
19 metformin. One retrospective cohort study investigated 276 glioblastoma patients15 
20 and found a trend towards improved PFS in diabetic patients treated with metformin 
21 in univariate analyses, but the associations were not observed in the multivariate 
22 model. A larger retrospective cohort study included 988 patients16 and suggested a 
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1 trend towards a survival benefit in diabetic patients using metformin (HR for OS=0.51, 
2 p=0.09). In a large study investigating survival of 1,093 patients with WHO grade III 
3 (n=231) or IV glioma (n=862) exposed to metformin, there was a significantly longer 
4 OS and PFS of patients with WHO grade III, but not WHO grade IV glioma.17 It was 
5 speculated that patients with IDH-mutated gliomas may experience more benefit 
6 from exposure to metformin.
7 For a definite insight into the therapeutic potential of metformin, randomized trials 
8 are needed. To further explore the likelihood of success of such a trial in patients with 
9 newly diagnosed glioblastoma, we used the opportunity to evaluate the effect of 
10 antidiabetics in a prospectively collected pooled dataset of 3 large multi-center 
11 randomized clinical trials. 
12
13 Patients and Methods 
14 Data source and study population
15 The patient population consisted of randomized patients from the control and 
16 experimental arms of the AVAGlio (NCT00943826; n=921),18 the CENTRIC 
17 (NCT00689221; n=545)19 and the CORE (NCT00813943; n=265)20 trials. All these trials 
18 were exploring the addition of a novel antiangiogenic agent added to the standard 
19 TMZ/RTTMZ backbone. All trials were aiming for registration and thus the data 
20 collected underwent close independent monitoring. Exploratory analyses adjusting 
21 for the level of glycemic control were performed with CENTRIC and CORE data only, 
22 since those variables were not routinely assessed in the AVAGlio trial.
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1 Trials were performed with approval by a local human investigations committee and 
2 in accordance with an assurance filed with and approved by the U.S. Department of 
3 Health and Human Services, where appropriate. Patient data were protected in 




8 Antidiabetic drug use
9 Metformin use was defined irrespective of whether it was used as monotherapy or in 
10 combination with other antidiabetic agents for the primary analysis. The category was 
11 further subclassified into metformin use as monotherapy during radio-chemotherapy 
12 (20 patients, 1.4%) and metformin use in combination with any other type of 
13 antidiabetic agent (combination therapy, 31 patients, 2.2%). Other antidiabetic drugs 
14 included insulin, sulphonylureas, thiazolidinediones (TDZ), alpha-glucosidase 
15 inhibitors, dipeptidyl peptidase-4 inhibitors (DPP4), and glinides.
16 The status of baseline metformin use or other baseline antidiabetic drug use was 
17 flagged as “positive” when they were used at any point in the period between the 
18 date of randomization minus two weeks and the date of the first TMZ treatment 
19 dose, and was flagged as “negative” otherwise. The status of respectively metformin 
20 use concomitant to the TMZ/RT treatment or other concomitant antidiabetic drug 
21 use was flagged as “yes” when they were used in the period between the first TMZ/RT 
22 treatment dose and start of the TMZ maintenance phase and “no” otherwise, as 
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1 described.21, 22 Different durations of baseline or concomitant use were summated, 
2 also for patients who used metformin on multiple occasions in the same or 
3 overlapping periods to account for the higher dose intensity for these patients. The 
4 day of initial surgery for glioblastoma was set as the earliest time point to compute 
5 the duration of use.
6
7 Statistical analysis
8 The first time point was fixed at the date of randomization to TMZ plus RT (TMZ/RT) 
9 in order to assess the association of baseline use with survival (period I). The second 
10 time point was set at the start of the TMZ maintenance phase (approximately 4 weeks 
11 after the end of the six weeks of TMZ/RT) in order to assess the association of use 
12 with outcome during initial treatment with temozolomide (TMZ/RT period, period II). 
13 For each univariate analysis that was performed, a Kaplan Meier survival plot was 
14 produced and estimates of the median survival time and estimated survival 
15 proportion at 1 year (PFS) and 2 years (OS) were computed. A non-parametric 
16 stratified log-rank test was implemented to test for differences between the survival 
17 distributions.
18 Cox models were used for multivariate survival analyses. Each model was adjusted for 
19 the prognostic factors age (continuous), gender (male or female), MGMT promotor 
20 methylation status (unmethylated, methylated or unknown), WHO performance status 
21 (status = 0 or status > 0), extent of initial resection (biopsy only, partial resection or 
22 complete resection), steroid use at baseline (yes or no), and MMSE score (score < 27 
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1 or score ≥ 27), and in addition stratified for trial. In the AVAGlio trial bevacizumab 
2 significantly improved PFS compared to the placebo group, therefore treatment arm 
3 was introduced as an additional stratification factor for this trial in the analysis of PFS. 
4 Significance was established at the 5% significance level. In the descriptive analyses 
5 frequencies with a difference of 10% or more were considered clinically relevant. 
6 Differences in steroid use were formally assessed with a chi square test.
7 We used SAS version 9.4 (SAS Institute Inc., Cary, NC) for description of baseline 




12 A total of 1,731 patients pooled from CENTRIC (545 patients), CORE (265 patients) 
13 and AVAGlio (921 patients) with newly diagnosed glioblastoma were assessed for 
14 survival according to use of metformin. The distribution of baseline demographic 
15 variables was similar over the three trials and four strata, except for MGMT promotor 
16 methylation status and extent of surgery. The two cilengitide trials were designed for 
17 patients with a methylated (CENTRIC) or unmethylated (CORE) tumor. In AVAGlio, 
18 MGMT promotor methylation data were missing in 24% of patients. These 
19 observations were therefore labeled as “unknown” as they would otherwise be lost 
20 during complete case survival analysis. Patients who finished the initial six weeks of 
21 TMZ/RT and continued with the TMZ maintenance period were younger than those 
22 who did not and more often male. They had a better WHO performance score, had 
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1 more often an MMSE score ≥ 27 and used less often steroids at baseline (39.4% vs. 
2 47.5%, p<0.01) (Table 1 and Appendix Table A1). 
3 In contrast, patients who used antidiabetic drugs at baseline were older than those 
4 who did not, more often male and had more often a WHO PS>0. Patients who used 
5 antidiabetic drugs other than metformin at baseline also used steroids more often at 
6 baseline compared to patients using metformin or no antidiabetics (other antidiabetic 
7 drugs: 52.0% vs. metformin: 41.9% vs. no use: 40.5%, p=0.27). Similar results were 
8 obtained for patients using antidiabetic drugs in the TMZ/RT period (Appendix Table 
9 A2).
10 A total of 124/1731 patients (7.2%) used any antidiabetic treatment at randomization. 
11 At the time of starting maintenance TMZ (approx. 4 weeks after the end of TMZ/RT) 
12 6.3% (89/1413) were receiving some antidiabetic treatment. Seventy-four patients 
13 (4.3%) received metformin at baseline (period 1), and 51 patients (3.6%) during period 
14 2. The distribution of baseline antidiabetic drug use and use during the TMZ/RT 
15 period in terms of prevalence, most common types, and duration of exposure was 
16 similar over the three trials and no differences were noted between the standard and 
17 bevacizumab arm of the AVAGlio trial (Appendix Table A3).
18 Association between metformin and survival
19 Baseline metformin use and metformin use during the TMZ/RT period was not 
20 statistically associated with a difference in OS or PFS compared to no use of 
21 metformin at baseline (HR for OS=0.87; 95%CI=0.65-1.16; HR for PFS=0.84; 
22 95%CI=0.64-1.10) or during the TMZ/RT period (HR for OS=0.97; 95%CI=0.68-1.38; 
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1 HR for PFS=1.02; 95%CI=0.0.74-1.41; Table 2, Appendix Tables A4-A9, Fig 1). Similar 
2 results were obtained for OS and PFS when metformin use was compared to no use 
3 of any antidiabetics (Table 2, Appendix Fig A1, Appendix Tables A8-A9). Although 
4 there was also no overall significant difference in OS or PFS when comparing 
5 metformin use as monotherapy or metformin use as combination therapy or use of 
6 other antidiabetic drugs to no use of antidiabetic drugs both at baseline (p for 
7 OS=0.364, p for PFS=0.072) and during TMZ/RT (p for OS=0.256, p for PFS=0.556) 
8 (Table 2, Appendix Fig A2, Appendix Tables A8-A9), there was a borderline 
9 statistically-significant HR for the baseline metformin monotherapy comparison for 
10 OS (HR=0.68; 95%CI=0.42-1.10) and a significant HR for PFS (HR=0.57; 95%CI=0.36-
11 0.91). During the TMZ/RT period the HR was 0.90 for OS (95%CI=0.51-1.56) and 1.05 
12 for PFS (95%CI=0.64-1.73). For antidiabetic drugs, other than metformin there was a 
13 trend for worse survival, especially when used during RT/TMZ (Table 2). 
14 Association between metformin and survival in the subgroup of patients with 
15 diabetes
16 Next, we performed analyses in the subgroup of patients with diabetes. Of all 
17 randomized patients, 150 (8.7%) had a history of diabetes and its distribution was 
18 similar over the three trials and four strata (Appendix Table A10). Baseline patient and 
19 clinical characteristics according to a history of diabetes are shown in Appendix Table 
20 A11. There was no statistically significant difference in OS or PFS when comparing 
21 patients with or without a history of diabetes after adjustment for important 
22 prognostic factors (Appendix Tables A12-A13). Among the subgroup of patients with 
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1 diabetes the use of metformin was not associated with OS or PFS, neither at baseline 
2 nor during the TMZ/RT period in none of the comparisons (Appendix Table A14). 
3 Association between metformin and survival according to glucose levels
4 Of all randomized patients in CENTRIC and CORE, 92.3% had a non-fasting glucose 
5 level 200 mg/dl (11.1mmol/l) at baseline. Patients with blood glucose values >11.1 
6 mmol/l at baseline or during TMZ/RT had more often used steroids at baseline 
7 (63.2% versus 38.2% and 53.6% versus 35.8%, Appendix Table A11 and data not 
8 shown) and more often used metformin in combination or other antidiabetic drugs 
9 compared to metformin as monotherapy or no use of antidiabetic drugs (Appendix 
10 Table A15). There was no statistically significant difference in OS or PFS between 
11 having a non-fasting blood glucose level >11.1mmol/l compared to ≤ 11.1mmol/l 
12 after adjustment for important prognostic factors at baseline (Appendix Table A16, 
13 results for PFS not shown) or during TMZ/RT (Appendix Table A17, results for PFS not 
14 shown). The HR for OS in patients with non-fasting blood glucose level >11.1mmol/l 
15 during TMZ/RT was 1.61 (95%CI=1.00-2.58). After additional adjustment for non-
16 fasting blood glucose levels, use of metformin was not associated with OS or PFS, 
17 neither at baseline nor during the TMZ/RT period in none of the comparisons 
18 (Appendix Table A18).
19
20 Discussion 
21 In this pooled analysis of three randomised prospective multi-centre clinical trials, the 
22 use of metformin was not associated with significant differences in OS or PFS in 
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1 patients with newly diagnosed glioblastoma. Similar results were obtained in the 
2 subset of patients with a history of diabetes or after adjustment for non-fasting 
3 glucose levels. We found a borderline statistically significant association of metformin 
4 monotherapy with glioblastoma survival at baseline, but not during RT/TMZ. Neither 
5 a diagnosis of diabetes nor the presence of increased non-fasting glucose levels was 
6 significantly associated with OS or PFS of glioblastoma patients in our cohort, but 
7 long-term measures of glycemic control were not available in our study.
8 A decreased overall survival in glioblastoma patients with diabetes as previously 
9 described 16,23 could not be demonstrated in our study. Similarly, persistently 
10 increased blood glucose levels were reported to be associated with reduced survival 
11 in patients with glioblastoma,24 high-grade glioma,23, 25 or low-grade glioma.26 Our 
12 analyses do not confirm these observations. Increased non-fasting blood glucose 
13 levels were not associated with worse survival although there was an indication for 
14 worse OS (HR=1.61; 95%CI=1.00-2.58) when detected during TMZ/RT. The present 
15 analysis differed from previous investigations because our study population consisted 
16 exclusively of patients with newly diagnosed glioblastoma and they were all treated 
17 with TMZ/RT standard treatment. Chambless et al. investigated patients with either 
18 WHO grade III or WHO grade IV glioma, which underwent different treatment 
19 regimens in a retrospective study. The small patient population consisted of 15 
20 patients (9%) with type 2 diabetes mellitus among the 171 patients with high-grade 
21 glioma. Furthermore, they adjusted only for a few key factors not including gender, 
22 steroid use at baseline, MGMT status and MMSE. We hypothesize that patients with 
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1 lower grade gliomas 23, 25,15 are more likely to experience survival-detrimental effects 
2 of diabetes or hyperglycemia due to their higher life expectancy as compared to 
3 patients with primary glioblastoma. Also, patients included in clinical trials are likely 
4 to be returning to clinic more frequently, undergoing more blood tests ultimately 
5 leading to a better glycemic control, while patients with an uncontrolled diabetes 
6 may be excluded upfront from the trial. The fact, that in our study over 90% of 
7 patients had documented normal blood glucose levels (≤ 11.1mmol/l) underscores 
8 this observation.
9 Survival of patients with glioblastoma after use of metformin has been investigated in 
10 only few prior studies. A study on 276 patients with primary glioblastoma did not 
11 demonstrate an increased PFS after adjustment for important confounding factors.15 
12 Welch et al. reported that use of metformin monotherapy was amongst the most 
13 important predictors for survival in their retrospective analysis on 988 patients.16 That 
14 study differs from ours, as it was not derived from a clinical trial population, pooled 
15 primary and secondary GBM, and included various oncologic treatment regimens. 
16 Patients also had a median glucose level of 198.5 mg/dl (including fasting and non-
17 fasting glucose levels) which is markedly higher than in our study (105 mg/dl, Q1: 
18 92.1 - Q3: 128), their study was not adjusted for MGMT status.16 In another 
19 retrospective study in 1,093 patients with high-grade glioma from South-East 
20 Germany, only patients with WHO grade III glioma had a significantly longer survival 
21 with metformin treatment (HR for OS=0.30; 95%CI=0.11-0.81), whereas patients with 
22 glioblastoma did not (HR=0.83; 95%CI=0.57-1.20).17 
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1 Our results are in contrast to several experimental preclinical studies suggesting 
2 inhibitory effects of metformin on glioma cells.6-12, 27-29 One major drawback of those 
3 studies may however be that metformin doses used in cell culture are frequently by 
4 far higher than the concentrations measured in the brain of diabetic patients. In vitro 
5 studies often used metformin doses in the millimolar [10-3, mM] range,6, 7, 9-12, 28, 29 
6 whereas metformin doses in the brain of diabetic patients have been measured in the 
7 micromolar [10-6, µM] range.30 Whether doses of metformin may be increased in 
8 patients with cancer as compared to patients with diabetes has not yet been 
9 investigated. Also, metformin doses in the µM range showed inhibitory effects on 
10 glioblastoma cells in extended treatments (7-15 days).10 Potentially, a subset of 
11 glioma patients with metabolic vulnerabilities may be more susceptible to 
12 metformin,31 for example patients with gliomas classified as a proneural subtype or 
13 gliomas harbouring mutations in the isocitrate dehydrogenase (IDH) genes,32 which 
14 could also explain the positive associations in grade III patients in one study.17 We 
15 were unable to stratify according to IDH-mutational status, because studies were 
16 performed before this marker was known or incorporated into routine practice. 
17 Nevertheless, the pooled trials were focusing on primary glioblastoma, thus less than 
18 5% of the tumors are expected to harbor an IDH mutation. 
19 Interestingly, even with low sample sizes, there was an indication for better survival in 
20 patients with metformin monotherapy at baseline, but this was not present when 
21 investigating use during TMZ/RT. Besides possible glioma-inhibitory effects of 
22 metformin monotherapy, it has to be considered that diabetic patients with less 
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1 severe and long-lasting diabetes may have been more likely to be treated with 
2 metformin monotherapy, which might explain those associations. On the other hand, 
3 steroid use due to increased intracranial pressure and clinical worsening may have led 
4 to diabetic decompensations and subsequent use of metformin. Thereby, any 
5 possible effects of metformin may have been negated by negative effects of steroids. 
6 Furthermore, one may speculate that missing survival-detrimental effects of diabetes 
7 may be related to beneficial effects of metformin in a significant number of diabetic 
8 patients leading to overall null associations.
9 Our study has several limitations: the analyses were unplanned and retrospective and 
10 the subgroups of patients treated with metformin were small representing less than 
11 7% of patients. Therefore, a lack of power may have led to false negative results. 
12 Further, we were not able to perform dose-response analyses i.e. investigating 
13 increasing doses and durations of metformin in relation to glioblastoma survival 
14 although there was a significant range of duration of metformin use between patients 
15 within the respective trials. However, we investigated metformin use at two different 
16 periods of time (at baseline and during TMZ/RT) and metformin is mostly used at 
17 stable drug doses of 1-2.5 g/day. We were not able to analyse long-term glycemic 
18 control using HbA1c values, repeated measures of short-term glycemic control using 
19 fasting glucose levels, levels of circulating insulin or injected insulin, or pre-existing 
20 hyperglycemia versus perioperative steroid induced hyperglycemia. Non-fasting 
21 glucose levels may well be confounded by glucose intake and may serve only as an 
22 inaccurate approximation for the investigation of glycemic control. Although 
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1 documentation of use of co-medications in patients within clinical trials is supposedly 
2 good, there may still be the possibility that co-medications were not completely 
3 documented. Possibly, patients with gliomas that already developed under metformin 
4 are resistant to the drug during the later course of disease. Therefore, metformin use 
5 before the diagnosis of glioma may have confounded our analysis on metformin and 
6 outcome of patients with primary glioblastoma. Finally, although we adjusted our 
7 analysis for multiple confounding factors, there may have been residual confounding 
8 for example due to older age and worse performance status in the group of patients 
9 on antidiabetic medication at baseline.     
10 In summary, we did not observe an association between the use of metformin and 
11 survival in patients with newly diagnosed glioblastoma. We conclude that, at least at 
12 commonly used therapeutic doses, metformin has no evident impact on outcome of 
13 patients with GBM, but those results are limited by the retrospective nature of our 
14 study and limited sample size.  
15 Additional prospective studies may identify patients with specific tumour 
16 characteristics that are associated with potential benefit from metformin. 
17
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1 Figure legends
2 Figure 1. Kaplan-Meier survival plots for use of metformin in any combination
3 A, B: Kaplan-Meier survival plots for OS (A) and PFS (B) at baseline according to use of 
4 metformin in any combination. 
5 C, D: Kaplan-Meier survival plots for OS (C) and PFS (D) according to use of 
6 metformin in any combination during TMZ/RT.
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(N = 1731) (N=318) (N=1413)
N (%) N (%) N (%)
Age (years)                                                        
Median                                         57.0              60.0              56.0              
Range                                      18.0 - 84.0       24.0 - 81.0       18.0 - 84.0       
Age category                                                                                                                                           
50                            1291 (74.6)                             269 (84.6)                           1022 (72.3)               
<50                              440 (25.4)                          49 (15.4)                           391 (27.7)                          
Gender                                                                                                                                                 
Male                            1026 (59.3)                             161 (50.6)                            865 (61.2)                          
Female                           705 (40.7)                          157 (49.4)                            548 (38.8)                          
Extent of Surgery                                                                                                                                      
Partial resection                835 (48.2)                          165 (51.9)                            670 (47.4)                          
Complete resection               789 (45.6)                          128 (40.3)                            661 (46.8)                          
Biopsy                           104 (6.0)                         25 (7.9)                           79 (5.6)                        
Missing                            3 (0.2)                                   0 (0.0)                          3 (0.2)                      
WHO Performance Status (PS)                                                                                                                                 
PS 0                             905 (52.3)                          123 (38.7)                            782 (55.3)                          
PS >0                            823 (47.5)                          192 (60.4)                            631 (44.7)                          
Missing                            3 (0.2)                                   3 (0.9)                          0 (0.0)                      
Steroid use at baseline                                                                                                                               
No                              1019 (58.9)                             166 (52.2)                            853 (60.4)                          
Yes                              708 (40.9)                          151 (47.5)                            557 (39.4)                          
Missing                            4 (0.2)                                   1 (0.3)                          3 (0.2)                      
MGMT                                                                                                                                                   
Methylated                       781 (45.1)                          151 (47.5)                            630 (44.6)                          
Unmethylated                     727 (42.0)                          123 (38.7)                            604 (42.7)                          
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Unknown                          223 (12.9)                          44 (13.8)                           179 (12.7)                          
MMSE                                                                                                                                                   
27                            1325 (76.5)                             207 (65.1)                           1118 (79.1)               
<27                              384 (22.2)                          102 (32.1)                            282 (20.0)                          
Missing                           22 (1.3)                          9 (2.8)                         13 (0.9)                        
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Table 2. Overview of adjusted estimates for the primary and secondary analyses.
OS PFSComparison Period Group
HR 95%CI p-value HR 95%CI p-value
Baseline Metformin (in any 
combination)
0.87 (0.65 - 1.16) 0.327 0.84 (0.64 - 1.10) 0.204Metformin use 
versus no 
metformin use TMZ/RT Metformin (in any 
combination)
0.97 (0.68 - 1.38) 0.854 1.02 (0.74 - 1.41) 0.912
Metformin (in any 
combination)
0.87 (0.65 - 1.16) 0.343 0.84 (0.64 - 1.11) 0.219Baseline
Other antidiabetics 1.14 (0.82 - 1.58) 0.434 1.19 (0.87 – 1.63) 0.284
Metformin (in any 
combination)








Other antidiabetics 1.46 (1.00 – 2.13) 0.05 1.32 (0.90 – 1.92) 0.151
Metformin 
(monotherapy)
0.68 (0.42 – 1.10) 0.115 0.57 (0.36 – 0.91) 0.019
Combination 
therapy
1.02 (0.72 - 1.46) 0.901 1.09 (0.79 – 1.51) 0.612
Baseline
Other antidiabetics 1.14 (0.82 - 1.58) 0.433 1.19 (0.87 – 1.63) 0.284
Metformin 
(monotherapy)
0.90 (0.51 - 1.56) 0.695 1.05 (0.64 - 1.73) 0.851
Combination 
therapy











Other antidiabetics 1.46 (1.00 – 2.13) 0.05 1.32 (0.90 – 1.92) 0.151
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Figure 1. Kaplan-Meier survival plots for use of metformin in any combination 
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